Get the Stockscreener App
8.05
0.00%
0.00
Vigil Neuroscience Inc stock is traded at $8.05, with a volume of 2.49M.
It is up +0.00% in the last 24 hours and up +1.00% over the past month.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
See More
Previous Close:
$8.05
Open:
$8.05
24h Volume:
2.49M
Relative Volume:
1.68
Market Cap:
$383.88M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-3.9078
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
+0.00%
1M Performance:
+1.00%
6M Performance:
+238.24%
1Y Performance:
+100.75%
1-Day Range:
$8.02
$8.06
1-Week Range:
$8.02
$8.07
52-Week Range:
$1.312
$8.10
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
8.05 | 375.71M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Initiated | William Blair | Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
What is Vigil Neuroscience Inc. company’s growth strategyEarnings Report Ideas With High Returns - jammulinksnews.com
Vigil Neuroscience Inc.’s Beta Climbs After Market VolatilityOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Price Consolidation Hints at Upcoming Move in Vigil Neuroscience Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Vigil Neuroscience Inc. Moves Into Bullish Territory Based on MACDBeginner Friendly Stock Selection Guide Updated - metal.it
Published on: 2025-07-30 12:06:12 - metal.it
Published on: 2025-07-30 04:41:09 - metal.it
Vigil Neuroscience Inc. Price Targets Raised After ReboundChart Breakout Buy Signal Detection Confirmed - metal.it
What analysts say about Vigil Neuroscience Inc. stock outlookStock Screener With Smart Filters Highlights Top Picks - metal.it
Published on: 2025-07-29 07:49:10 - metal.it
Trading Bots Trigger Alerts on Vigil Neuroscience Inc. ActivityBuy Signal Based on Chart Analysis Confirmed - metal.it
What are the technical indicators suggesting about Vigil Neuroscience Inc.Stock Strategy Review That Work - jammulinksnews.com
Vigil Neuroscience Faces Stockholder Demands Post-Merger - TipRanks
Vigil Neuroscience issues supplemental disclosures on Sanofi merger following shareholder demands By Investing.com - Investing.com South Africa
Vigil Neuroscience issues supplemental disclosures on Sanofi merger following shareholder demands - Investing.com Nigeria
What catalysts could drive Vigil Neuroscience Inc. stock higher in 2025Capitalize on stocks with high profit margins - jammulinksnews.com
What are Vigil Neuroscience Inc. company’s key revenue driversTrack top-performing stocks in real-time - jammulinksnews.com
Why is Vigil Neuroscience Inc. stock attracting strong analyst attentionCapitalize on fast-moving stock opportunities - jammulinksnews.com
How volatile is Vigil Neuroscience Inc. stock compared to the marketAccelerated financial growth - jammulinksnews.com
What is the dividend policy of Vigil Neuroscience Inc. stockCapitalize on strategic market trends - jammulinksnews.com
Is Vigil Neuroscience Inc. a good long term investmentTremendous gains - PrintWeekIndia
Does Vigil Neuroscience Inc. stock pay reliable dividendsOutstanding risk-reward balance - jammulinksnews.com
What drives Vigil Neuroscience Inc. stock priceFree Capital Growth Strategies - Autocar Professional
Vigil Neuroscience Inc. Stock Analysis and ForecastRapid wealth creation - PrintWeekIndia
How high can Vigil Neuroscience Inc. stock price go in 2025Exceptional trading performance - jammulinksnews.com
What analysts say about Vigil Neuroscience Inc. stockFree Investment Community - jammulinksnews.com
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vigil Neuroscience Inc Stock (VIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):